Remove zydus-daewoong-sign-licensing-pact-to-develop-market-leuprolide-long-acting-injectable-in-us
article thumbnail

Zydus, Daewoong sign licensing pact to develop, market Leuprolide long-acting injectable in US

Express Pharma

Zydus Worldwide DMCC, a wholly owned subsidiary of Zydus Lifesciences and Daewoong Pharmaceutical Co announced that they have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot, AbbVie) in six dosage strengths for the United States (US) market.

Dosage 105